EDIT - Editas Medicine Inc
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
19%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -48.37%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -701.06%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 3.08
Debt Ratio is 0.76
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.21
Cash Flow is WEAK
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Editas Medicine Inc (EDIT) - http://www.editasmedicine.com/
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.Exchange - NASDAQ
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO - Cynthia Collins
Employees - 297
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.